Breaking News Instant updates and real-time market news.

CLLS

Cellectis

$14.60

0.255 (1.78%)

13:19
12/03/19
12/03
13:19
12/03/19
13:19

Cellectis CEO says company's core remains gene-editing

Cellectis (CLLS) develops immunotherapies based on gene-edited CAR T-cells. In an exclusive interview with The Fly, the company's CEO Andre Choulika talked about the company's focus on gene-editing: "Well Cellectis is a biotech company that had been founded as a gene editing company and I think we're the first gene-editing company to ever be founded. That was like close to 20 years ago and since then we have kept the core technology of the company in gene-editing. Today 100% of our products are in oncology, 100% of them are CAR-T therapies and 100% of the indications are liquid tumors. Nevertheless, the core remains gene-editing and we potentially will expand outside oncology and other types of indications using gene-editing as the core technology there." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

  • 03

    Dec

  • 07

    Dec

CLLS Cellectis
$14.60

0.255 (1.78%)

03/14/19
WBLR
03/14/19
INITIATION
WBLR
Outperform
William Blair starts Cellectis with Outperform rating, $33 fair value estimate
William Blair analyst Raju Prasad last night initiated coverage of Cellectis with an Outperform rating and $33 fair value estimate. The company has seen a depressed valuation since the Allogene licensing deal, but the economics from the partnership and equity stake in Calyxt "set a valuation floor," Prasad tells investors in a research note. The analyst sees UCART123 being developed for acute myeloid leukemia and UCARTCS1 being developed for multiple myeloma as "riskier targets." However, he believes the CD22 target for acute lymphoblastic leukemia and non-Hodgkin lymphoma have been "de-risked from autologous therapies and could support upside."
05/24/19
SBSH
05/24/19
INITIATION
Target $22
SBSH
Neutral
Cellectis assumed with a Neutral at Citi
Citi analyst Yigal Nochomovitz assumed coverage of Cellectis with a Neutral rating and $22 price target. The analyst sees limited stock moving catalysts in the near-term, with UCART123 dose expansion data only in 2020.
08/09/19
BTIG
08/09/19
INITIATION
BTIG
Buy
Cellectis initiated with a Buy at BTIG
08/09/19
BTIG
08/09/19
INITIATION
Target $37
BTIG
Buy
Cellectis initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Cellectis with a Buy rating and a price target of $37 as part of her broader research note on CAR-T cell therapy names developing "off-the-shelf" engineered cell therapeutics for oncology. The analyst is positive on the company's partnership and collaboration agreements from its CAR-T pipeline deals with upcoming catalysts that include initial data from the ongoing Phase 1 study evaluating UCART123 for AML and the enrollment and dosing of the first patient in ' Phase 1 study evaluating UCART22 in AL expected this year.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$314.12

0.25 (0.08%)

, SPX

S&P 500

$0.00

(0.00%)

14:30
12/10/19
12/10
14:30
12/10/19
14:30
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

McConnell says Senate…

SPY

SPDR S&P 500 ETF Trust

$314.12

0.25 (0.08%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$34.60

0.76 (2.25%)

14:27
12/10/19
12/10
14:27
12/10/19
14:27
Recommendations
MorphoSys analyst commentary  »

MorphoSys sounds close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEP

American Electric

$91.94

0.045 (0.05%)

14:23
12/10/19
12/10
14:23
12/10/19
14:23
Hot Stocks
PSO reaches settlement pact with Public Utility Division Staff of OCC »

Public Service Company of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CORV

Correvio

$1.39

(0.00%)

14:22
12/10/19
12/10
14:22
12/10/19
14:22
Periodicals
FDA panel said to vote against recommending approval for Correvio's Brinavess »

SAC Tracker, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

14:20
12/10/19
12/10
14:20
12/10/19
14:20
General news
The Europe Brief: »

The Europe Brief:…

EVH

Evolent Health

$9.02

1.125 (14.25%)

14:17
12/10/19
12/10
14:17
12/10/19
14:17
Recommendations
Evolent Health analyst commentary  »

William Blair says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/10/19
12/10
14:17
12/10/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/10/19
12/10
14:16
12/10/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONN

Conn's

$14.09

-6.42 (-31.30%)

14:03
12/10/19
12/10
14:03
12/10/19
14:03
Downgrade
Conn's rating change  »

Conn's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

CONN

Conn's

$14.08

-6.43 (-31.35%)

13:59
12/10/19
12/10
13:59
12/10/19
13:59
Downgrade
Conn's rating change  »

Conn's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

EVH

Evolent Health

$8.46

0.565 (7.16%)

13:59
12/10/19
12/10
13:59
12/10/19
13:59
Periodicals
Kentucky committee rejects outgoing governor's 'snub' of Evolent, LBF says »

The Government Contract…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDR

UDR, Inc.

$47.78

-0.11 (-0.23%)

13:56
12/10/19
12/10
13:56
12/10/19
13:56
Conference/Events
UDR, Inc. management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

XOM

Exxon Mobil

$68.73

-0.93 (-1.34%)

13:54
12/10/19
12/10
13:54
12/10/19
13:54
Hot Stocks
Exxon: Ruling affirms position company has held throughout 'baseless' probe »

ExxonMobil issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ADPT

Adaptive Biotechnologies

$29.09

-0.21 (-0.72%)

13:54
12/10/19
12/10
13:54
12/10/19
13:54
Conference/Events
Adaptive Biotechnologies management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVGO

Livongo Health

$25.83

-1.57 (-5.73%)

13:52
12/10/19
12/10
13:52
12/10/19
13:52
Recommendations
Livongo Health analyst commentary  »

Livongo Health valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WDFC

WD-40

$194.62

-1.12 (-0.57%)

13:51
12/10/19
12/10
13:51
12/10/19
13:51
Hot Stocks
WD-40 increases quarterly dividend nearly 10% »

WD-40 Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

13:50
12/10/19
12/10
13:50
12/10/19
13:50
General news
Treasury Action: the Treasury market is unmoved »

Treasury Action: the…

13:49
12/10/19
12/10
13:49
12/10/19
13:49
Conference/Events
JPMorgan consumer finance analyst to hold analyst/industry conference call »

Specialty & Consumer…

EVH

Evolent Health

$8.27

0.375 (4.75%)

13:49
12/10/19
12/10
13:49
12/10/19
13:49
Hot Stocks
Evolent Health jumps $1.55, or 20%, to $9.42 »

Contacts tell The Fly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
12/10/19
12/10
13:45
12/10/19
13:45
Conference/Events
JPMorgan semiconductors anayst to hold an analyst/industry conference call »

Semiconductors,…

NFLX

Netflix

$297.38

-5.1 (-1.69%)

13:45
12/10/19
12/10
13:45
12/10/19
13:45
Hot Stocks
Netflix says 'really proud' of animation work, cadence of films picking up »

Speaking at the UBS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

13:41
12/10/19
12/10
13:41
12/10/19
13:41
Conference/Events
JPMorgan restaurants analyst to hold an analyst/industry conference call »

Restaurants Analyst…

VALE

Vale

$12.35

-0.035 (-0.28%)

13:33
12/10/19
12/10
13:33
12/10/19
13:33
Conference/Events
Morgan Stanley materials analyst holds an analyst/industry conference call »

Head of Australia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$14.24

0.075 (0.53%)

13:33
12/10/19
12/10
13:33
12/10/19
13:33
Hot Stocks
CenturyLink pays Washington $6.1M to settle hidden fees lawsuit »

Washington Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CI

Cigna

$190.30

-5.59 (-2.85%)

, MET

MetLife

$49.25

-0.315 (-0.64%)

13:31
12/10/19
12/10
13:31
12/10/19
13:31
Periodicals
New York Life in talks to buy nonmedical insurance unit from Cigna, WSJ reports »

New York Life Insurance…

CI

Cigna

$190.30

-5.59 (-2.85%)

MET

MetLife

$49.25

-0.315 (-0.64%)

SLF

Sun Life Financial

$44.95

0.465 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Feb

  • 13

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.